EMA Authorised: Replagal (agalsidase alfa) — Takeda Pharmaceuticals International AG Ireland Branch

View source ↗

Summary

The EMA authorised Replagal (agalsidase alfa) for treatment of Fabry disease, with Takeda Pharmaceuticals International AG Ireland Branch as the marketing autho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• Replagal (agalsidase alfa)

Snippet

Status: Authorised. Therapeutic area: Fabry Disease. MAH: Takeda Pharmaceuticals International AG Ireland Branch. Decision date: 17/12/2025